Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Controlled human infection model with toxigenic Clostridioides difficile in healthy adults
NL-OMON57376Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of vancomycin and clindamycin in Clostridioides difficile colitis (CDI) (3 cohorts), sponsored by Leiden University Medical Center. Primary endpoints: Safety, Proven microbiological colonization endpoint and 3 more. Started May 2025; status: recruiting.
02
Drugs
vancomycinclindamycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on NL-OMON57376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57376.